atorvastatin has been researched along with amlodipine in 148 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 57 (38.51) | 29.6817 |
| 2010's | 66 (44.59) | 24.3611 |
| 2020's | 25 (16.89) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; van de Poll, SW; van der Laarse, A | 1 |
| Ostroumova, OD | 1 |
| Delsing, DJ; Havekes, LM; Princen, HM; Puppels, GJ; van de Poll, SW; van der Laarse, A; Wouter Jukema, J | 1 |
| Delsing, DJ; Emeis, JJ; Havekes, LM; Jukema, JW; Princen, HM; van de Wiel, MA; van der Laarse, A | 1 |
| Beniashvili, M; Freiman, A; Gavish, D; Leibovitz, E; Shargorodsky, M; Zimlichman, R | 1 |
| Jukema, JW; van der Hoorn, JW | 1 |
| Frishman, WH; Zuckerman, AL | 1 |
| Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A | 1 |
| Anderson, T; Boudreau, G; Buithieu, J; Chan, S; Charbonneau, F; Dorval, JF; Genest, J; Hutchison, S; Huynh, T; Jobin, J; Lonn, E; Poirier, P; Title, L; Tran, T; Walling, A | 1 |
| Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L | 1 |
| Cowie, MR | 1 |
| Bauer, B; Böhler, S; da Silva, PM; Feldman, R; Genest, J; Gensini, G; Harvey, P; Hobbs, FD; Jenssen, TG; Mancini, GB; Manolis, AJ; Metcalfe, M | 1 |
| Mason, RP | 2 |
| de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A | 1 |
| Blank, R | 1 |
| Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W | 1 |
| Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A | 1 |
| Bramson, C; Calcagni, A; Chung, M; Glue, P | 2 |
| Ansari Dogaheh, M; Ghorbani Bidkorbeh, F; Hashem, M; Mohammadi, A; Rezanour, N; Walker, RB | 1 |
| Császár, A | 1 |
| Blanco-Colio, LM; Duran, MC; Egido, J; Martín-Ventura, JL; Tuñon, J; Vivanco, F | 1 |
| Chaudhari, BG; Patel, NM; Shah, PB | 1 |
| Messerli, FH | 1 |
| Anderson, TJ; Buithieu, J; Chan, S; Charbonneau, F; Genest, J; Hutchison, S; Huyhn, T; Jobin, J; Lonn, E; Poirier, P; Title, L; Tran, T; Walling, A | 1 |
| Bax, WH; Jukema, JW; Schutte-Bart, C; Trion, A; van der Laarse, A | 1 |
| Hu, ZJ; Liu, DL; Wang, MP; Wu, G; Wu, J; Xu, GY | 1 |
| Manavalan, R; Muralidharan, C; Sivakumar, T; Valliappan, K | 1 |
| Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F | 1 |
| Hobbs, FD | 1 |
| Day, CA; Funovics, P; Heeba, G; Jacob, RF; Kubant, R; Malinski, T; Mason, RP; Medlin, YS | 1 |
| Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K | 1 |
| McKeage, K; Siddiqui, MA | 1 |
| Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF | 1 |
| Doggrell, SA | 1 |
| Mehlsen, J | 1 |
| Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF | 1 |
| Kékes, E | 1 |
| Foody, JM; Honda, D; Leslie, RS; Nichol, MB; Patel, BV; Solomon, H; Tang, SS; Thiebaud, P | 1 |
| Chen, GP; Hu, SJ; Lu, X; Mou, Y; Yao, L; Zheng, LR | 1 |
| Bartoletti, R; Cai, T; Mazzoli, S; Mondaini, N | 1 |
| Blanco-Colio, LM; Egido, J; Madrigal-Matute, J; Martín-Conejero, A; Martín-Ventura, JL; Muñoz-Garcia, B; Ortega, L; Serrano, J; Vega, M | 1 |
| Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ | 1 |
| Bestermann, WH; Dyess, EM; Graff, A; Kursun, A; Neutel, JM; Sutradhar, S; Yunis, C | 1 |
| Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Byun, J; Jacob, RF; Mason, RP; Mizuno, Y; Self-Medlin, Y | 1 |
| Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD | 1 |
| Cui, W; Du, J; Han, M; Liu, DM; Liu, F; Lu, JC; Yin, HN; Zhang, HL; Zhang, K | 1 |
| Bangalore, S; Devabhaktuni, M | 1 |
| Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK | 1 |
| Hughes, AD; Manisty, C; Mayet, J; McG Thom, SA; Poulter, N; Sever, PS; Tapp, RJ | 1 |
| Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K | 1 |
| Ko, SK; Liew, D; Park, HJ | 1 |
| Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Benner, JS; Chapman, RH; Foody, JM; Hussein, MA; Joyce, A; Solomon, HA; Tang, SS | 1 |
| Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C | 1 |
| Derosa, G; Maffioli, P | 1 |
| Chapman, RH; Roberts, CS; Yeaw, J | 1 |
| Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C | 1 |
| Inamadugu, JK; Karra, VK; Mullangi, R; Pilli, NR; Rao, JV; Vaidya, JR | 1 |
| Lopatin, IuM | 1 |
| Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X | 1 |
| Hagita, S; Osaka, M; Shimokado, K; Yoshida, M | 1 |
| Hirata, Y; Sata, M | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T | 1 |
| Al-Khadra, A; Erdine, S; Kim, JH; Pavia, A; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X | 1 |
| Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S | 1 |
| Alves, K; Garg, V; Lee, JE; Smith, F; van Heeswijk, R | 1 |
| Darwish, HW; El-Zeiny, BA; Hassan, SA; Salem, MY | 1 |
| Anderson, L; Bhattacharya, S; Bose, N; Fraser, E; Graham, K; Lumsden, G; McClue, L; Robertson, L; Tho, LM; Yosef, H | 1 |
| Kishi, T; Sunagawa, K | 1 |
| Delgado-Montero, A; Zamorano, JL | 1 |
| Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY | 2 |
| Abe, K; Deguchi, K; Deguchi, S; Kawai, H; Kono, S; Kurata, T; Ohta, Y; Omote, Y; Yamashita, T | 1 |
| Alawi, M; Arafat, T; Awwad, AA; Yacoub, M | 1 |
| Spence, JD | 1 |
| Hradec, J; Sutradhar, S; Zamorano, J | 1 |
| Fan, Y; He, X; Jia, M; Li, H; Li, J; Li, W; Liu, M; Xiong, Z; Zhou, Y | 1 |
| Do e, Z; Fukumoto, Y; Kanazawa, M; Matsumoto, Y; Sato, A; Satoh, K; Shimizu, T; Shimokawa, H; Takahashi, K | 1 |
| Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y | 1 |
| Jaimes, EA; Raij, L; Tian, R; Zhou, MS | 1 |
| Azushima, K; Dejima, T; Kanaoka, T; Kobayashi, R; Maeda, A; Ohsawa, M; Tamura, K; Toya, Y; Umemura, S; Uneda, K; Wakui, H | 1 |
| Chabouk, M; Ejlali, M; Panahi, HA | 1 |
| de Ceuninck, M; Trenson, S | 1 |
| Kartashova, EA; Romantsov, MG; Sarvilina, IV | 1 |
| O'Brien, E | 1 |
| Balakhonova, T; Boytsov, S; Deev, A; Kolos, I; Shariya, M; Skrypnik, D; Troitskiy, A; Tvorogova, T | 1 |
| Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X | 1 |
| Ferenci, T; Simonyi, G | 1 |
| Bertrand, ME; Mourad, JJ; Vlachopoulos, C | 1 |
| Cui, W; Du, H; Hao, J; Li, Y; Lu, J; Xiao, B; Yang, X | 1 |
| Chen, F; Chen, H; Cui, W; Jin, Y; Liu, D; Liu, F; Lu, J | 1 |
| Wang, M; Zeng, R; Zhang, L | 1 |
| Hammad, MA; Mohamed, AA; Mohamed, AI; Omar, MA | 1 |
| El-Zeany, SB; Elzanfaly, ES; Hassan, SA; Salem, MY | 1 |
| Badhan, RK; Dennison, TJ; Mohammed, AR; Smith, JC | 1 |
| Kundzina, L; Lejniece, S | 1 |
| Radermecker, RP | 1 |
| Bartlett, LE; Pratt, N; Roughead, EE | 1 |
| Badr, KA; Rezk, MR | 1 |
| Dézsi, CA | 1 |
| Collier, T; Godec, T; Gupta, A; Mackay, J; Pocock, S; Poulter, N; Sever, P; Whitehouse, A | 1 |
| Ashcroft, JA | 1 |
| Gamou, T; Hayashi, K; Ino, H; Sakata, K; Tada, H; Yamagishi, M | 1 |
| Fares, NV; Farouk, M; Hemdan, A; Magdy, R | 1 |
| Dézsi, CA; Simon, A | 1 |
| Kim, JR; Kim, S; Ko, JW | 1 |
| Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Marzolini, C; Spaggiari, D | 1 |
| Nasr, JJ; Shalan, S | 1 |
| Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M | 1 |
| Blot, WJ; Gonzales, H; Miller, R; Muñoz, D; Munro, H; Pappalardo, S; Reynolds, C; Song, W; Tousey, P; Uzoije, P; Walkley, D; Wang, TJ; White, C | 1 |
| Gao, S; Li, J; Liu, P; Lu, K; Qian, L; Wang, M; Wu, X | 1 |
| Dwivedi, H; Pathak, K; Porwal, A | 1 |
| Abate, N; Chandalia, M; Jialal, I; Sallam, HS; Tuvdendorj, DR | 1 |
| Tůmová, E; Vrablík, M | 1 |
| Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M | 1 |
| Gao, S; Liu, H; Liu, P; Lu, K; Wang, H; Wu, X | 1 |
| Baba, Y; Hirota, T; Kawada, Y; Kitaoka, H; Kubo, T; Tanioka, K; Yamasaki, N | 1 |
| Gundlach, K; Randerath, O; Salem, I; Seiler, D; Wolf, K | 1 |
| Kondratenko, S; Kukes, V; Melnikov, E; Shikh, E; Zozina, V | 1 |
| Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH | 1 |
| Glick, A; Johnson, C; Sista, V | 1 |
| Ancion, A; Lancellotti, P; Scheen, AJ | 1 |
| Gundlach, K; Hermann, R; Seiler, D | 1 |
| Chan, JYW; Cheung, DWS; Fung, KP; Ko, ECH; Koon, JCM; Lau, VKM; Wat, ECL; Waye, MMY; Wong, PH; Yau, KC | 1 |
| Godec, T; Gupta, AK; Mackay, J; Rostamian, S; Sever, PS; Whitehouse, A; Whiteley, WN | 1 |
| Al-Mohammadi, OS; Al-Qaaneh, AM; Mustafa, SM; Obaid, WT; Rabaan, AA | 1 |
| El-Naem, OA; Erk, N; Lotfy, HM; Saleh, SS; Tiris, G | 1 |
| Patel, A; Prajapati, P; Shah, S | 1 |
| Borghi, C; Cicero, AFG; D'Addato, S; Fogacci, F; Giovannini, M; Rizzoli, E | 1 |
| Qiu, Y; Yang, G | 1 |
| Abdulaziz, O; Ahmad, S; Ali, N; Ali, W; Aljuaid, A; Allahyani, M; Almehmadi, M; Alsaiari, AA; Ullah, A | 1 |
| Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW | 1 |
| Fan, H; Liu, Z; Luo, W; Ouyang, F; Tang, L; Yan, Y; Yang, H; Yuan, W | 1 |
17 review(s) available for atorvastatin and amlodipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy.
Topics: Amlodipine; Animals; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Combined Modality Therapy; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Pyrroles | 2004 |
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2004 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles; Risk Factors; Treatment Outcome | 2005 |
A single-pill combination of amlodipine besylate and atorvastatin calcium.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles; Tablets | 2006 |
[Vascular pleiosynergism--a new concept?].
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Carrier Proteins; Cell Movement; Cell Proliferation; Cytokines; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocytes, Smooth Muscle; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Reactive Oxygen Species; Vascular Diseases | 2006 |
Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
Topics: Amlodipine; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2006 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Guidelines as Topic; Heptanoic Acids; Humans; Pyrroles; Risk Factors | 2007 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2008 |
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Quality of Life; Treatment Outcome | 2009 |
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pyrroles | 2010 |
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Combined Modality Therapy; Humans; Perindopril; Risk Factors | 2016 |
[Lipertance® The ASCOT single-pill combination has finally arrived].
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Humans; Hypertension; Perindopril; Risk Factors | 2017 |
40 trial(s) available for atorvastatin and amlodipine
| Article | Year |
|---|---|
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Therapy, Combination; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Tissue Plasminogen Activator | 2004 |
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha | 2006 |
Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet.
Topics: Adolescent; Adult; Amlodipine; Atorvastatin; Biological Availability; Cross-Over Studies; Drug Combinations; Female; Health; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Tablets | 2006 |
Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet.
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Area Under Curve; Atorvastatin; Biological Availability; Cross-Over Studies; Dietary Fats; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Drug Combinations; Female; Food-Drug Interactions; Half-Life; Headache; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Tablets; Therapeutic Equivalency | 2006 |
Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX).
Topics: Adult; Aged; Amlodipine; Apolipoproteins B; Atorvastatin; Biomarkers; Blood Pressure; Brachial Artery; Calcium Channel Blockers; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography; Vasodilation | 2008 |
[Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China].
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzazepines; Carotid Arteries; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media | 2007 |
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspartate Aminotransferases; Atorvastatin; Blood Pressure; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles; Treatment Outcome | 2007 |
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2008 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Uric Acid; Ventricular Remodeling | 2008 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Treatment Outcome | 2009 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Carotid Artery Diseases; Carotid Stenosis; Chemokine CCL2; Cholesterol, LDL; Drug Synergism; Female; Heptanoic Acids; Humans; Hypertension; Macrophages; Male; Middle Aged; NF-kappa B; Pyrroles; RNA, Messenger | 2008 |
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebos; Pyrroles | 2009 |
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Life Style; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2009 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Risk Factors; Risk Reduction Behavior; Sodium Chloride Symporter Inhibitors | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Tablets; Treatment Outcome | 2009 |
Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Cross-Over Studies; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Severity of Illness Index; Single-Blind Method | 2011 |
Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
Topics: Aged; Amlodipine; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure Determination; Carotid Arteries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Pulsatile Flow; Pyrroles; Reproducibility of Results; Scandinavian and Nordic Countries; Severity of Illness Index; United Kingdom; Vasodilator Agents | 2009 |
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cluster Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Internationality; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Surveys and Questionnaires | 2010 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Disease; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Young Adult | 2010 |
Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Preventive Health Services; Pyrroles; Risk Factors; Standard of Care | 2011 |
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Blood Pressure; Cholesterol; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome | 2011 |
Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.
Topics: Adult; Amlodipine; Antiviral Agents; Atorvastatin; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Female; Hepacivirus; Heptanoic Acids; Humans; Male; Middle Aged; Oligopeptides; Peptide Hydrolases; Protease Inhibitors; Pyrroles | 2011 |
Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS.
Topics: Administration, Oral; Amlodipine; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Combinations; Drug Stability; Heptanoic Acids; Humans; Isomerism; Linear Models; Pravastatin; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Therapeutic Equivalency | 2013 |
Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors | 2013 |
[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Atorvastatin; Blood Pressure; Blood Proteins; Drug Combinations; Drug Therapy, Combination; Echocardiography; Female; Flavin Mononucleotide; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Hypertensive Encephalopathy; Inosine Diphosphate; Male; Neuroprotective Agents; Niacinamide; Pyrroles; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinates; Systole; Tetrazoles; Valine; Valsartan | 2014 |
Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis.
Topics: Aged; Amlodipine; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Life Style; Male | 2015 |
Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Amlodipine; Atorvastatin; Biological Availability; Caco-2 Cells; Cardiovascular Diseases; Cells, Cultured; Dose-Response Relationship, Drug; Drug Compounding; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Reproducibility of Results; Tablets; Young Adult | 2017 |
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Risk Factors; United Kingdom | 2018 |
Low Baseline High-Sensitive C-Reactive Protein is Associated with Coronary Atherosclerosis Regression: Insights from the MILLION Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Prospective Studies | 2019 |
Pharmacokinetic and Safety Profiles of a Fixed-Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3-Period Replicate Crossover Study.
Topics: Adult; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Combinations; Humans; Male; Therapeutic Equivalency; Valsartan; Young Adult | 2020 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Health Centers; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Medically Underserved Area; Medication Adherence; Middle Aged | 2019 |
Therapeutic lifestyle change intervention improved metabolic syndrome criteria and is complementary to amlodipine/atorvastatin.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Behavior Therapy; Biomarkers; Blood Pressure; Cardiometabolic Risk Factors; Combined Modality Therapy; Drug Combinations; Female; Heptanoic Acids; Humans; Life Style; Lipids; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Placebos; Pyrroles; Risk Reduction Behavior | 2020 |
Safety of Candesartan, Amlodipine, and Atorvastatin in Combination: Interaction Study in Healthy Subjects.
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Area Under Curve; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Tetrazoles; Young Adult | 2021 |
Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial.
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Humans; Hypertension; Microcirculation; Receptors, Retinoic Acid; RNA; T-Lymphocytes, Regulatory; Th17 Cells | 2023 |
Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia.
Topics: Amlodipine; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Hypertension; Leukemia, Myeloid, Acute; Rosuvastatin Calcium; Treatment Outcome | 2023 |
Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway.
Topics: Aged; Amlodipine; Animals; Atorvastatin; Essential Hypertension; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Janus Kinases; Rats; Rats, Inbred SHR; Signal Transduction; STAT Transcription Factors | 2023 |
92 other study(ies) available for atorvastatin and amlodipine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Cholesterol; Disease Models, Animal; Drug Synergism; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles; Spectrum Analysis, Raman | 2002 |
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Isoquinolines; Pyrroles; Quinapril; Tetrahydroisoquinolines | 2002 |
Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Cholesterol; Heptanoic Acids; Humans; Mice; Mice, Transgenic; Pyrroles; Triglycerides | 2003 |
Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice.
Topics: Amlodipine; Animals; Aorta, Thoracic; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol; Cholesterol, Dietary; Drug Therapy, Combination; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles | 2003 |
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteries; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Diastole; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Stroke Volume; Systole; Treatment Outcome; Vascular Resistance | 2003 |
Amlodipine/atorvastatin (Caduet).
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles | 2004 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Doxazosin; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Sodium Chloride Symporter Inhibitors; Treatment Outcome | 2005 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Multicenter Studies as Topic; Pyrroles; Surveys and Questionnaires; Tablets | 2006 |
A rationale for combination therapy in risk factor management: a mechanistic perspective.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Disease Management; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Humans; Nitric Oxide; Pyrroles; Risk Factors | 2005 |
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein; von Willebrand Factor | 2006 |
A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tablets | 2007 |
Stability indicating RP-HPLC method for simultaneous determination of atorvastatin and amlodipine from their combination drug products.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Heptanoic Acids; Hydrolysis; Oxidative Stress; Photolysis; Pyrroles; Quality Control; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Temperature; Time Factors | 2007 |
Amlodipine/atorvastatin for preventing heart disease.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Drug Combinations; Heart Diseases; Heptanoic Acids; Humans; Pyrroles | 2007 |
Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination.
Topics: Amlodipine; Animals; Animals, Newborn; Aorta; Apoptosis; Ascorbic Acid; Atorvastatin; Calcinosis; Calcium; Cell Proliferation; Cell Separation; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Space; Heptanoic Acids; Muscle, Smooth, Vascular; Phosphates; Pyrroles; Rats; Rats, Wistar | 2008 |
An improved HPLC method with the aid of a chemometric protocol: simultaneous analysis of amlodipine and atorvastatin in pharmaceutical formulations.
Topics: Amlodipine; Atorvastatin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Heptanoic Acids; Models, Chemical; Molecular Structure; Pyrroles; Reproducibility of Results; Sensitivity and Specificity | 2007 |
Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction.
Topics: Amlodipine; Atorvastatin; Blotting, Western; Calcium Channel Blockers; Cells, Cultured; Drug Synergism; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Bilayers; Lipoproteins, LDL; Membrane Lipids; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Pyrroles; Vascular Diseases; X-Ray Diffraction | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumethiazide; Cardiovascular Diseases; Cost-Benefit Analysis; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Treatment Outcome | 2008 |
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen.
Topics: Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles; Retrospective Studies | 2008 |
Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blotting, Western; Calcium-Binding Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cytokines; Enzyme-Linked Immunosorbent Assay; Gene Expression; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Ventricular Function, Left | 2009 |
A possible negative effect of co-administered amlodipine and atorvastatin on semen volume and spermatozoa in men.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Databases, Factual; Drug Interactions; Fertility; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Semen; Spermatozoa | 2008 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Models, Economic; Pyrroles; Scandinavian and Nordic Countries; Treatment Outcome | 2009 |
Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation.
Topics: Amlodipine; Atorvastatin; Cell Membrane; Cholesterol; Glucose; Heptanoic Acids; Lipid Peroxidation; Membrane Lipids; Oxidative Stress; Phospholipids; Pyrroles; X-Ray Diffraction | 2009 |
Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Drug Synergism; Drug Therapy, Combination; Fibrosis; Heart Failure, Diastolic; Hemodynamics; Heptanoic Acids; Myocytes, Cardiac; NADPH Oxidases; Natriuretic Peptide, Brain; Oxidative Stress; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Superoxide Dismutase; Ventricular Dysfunction, Left | 2009 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2009 |
Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Korea; Male; Markov Chains; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Risk Factors | 2009 |
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Managed Care Programs; Medication Adherence; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies | 2010 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Patient Compliance; Pyrroles; Retrospective Studies; United States | 2010 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Databases, Factual; Drug Therapy, Combination; Female; Health Records, Personal; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk; Risk Factors; Risk Reduction Behavior | 2010 |
Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzazepines; Chromatography, Liquid; Drug Stability; Heptanoic Acids; Humans; Least-Squares Analysis; Male; Nevirapine; Pyrroles; Ramipril; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Monitoring; Drug Synergism; Dyslipidemias; Heart Diseases; Heptanoic Acids; Humans; Hypertension; Patient Compliance; Pyrroles; Risk Factors | 2010 |
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity; Data Interpretation, Statistical; Dyslipidemias; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Hematocrit; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Time Factors | 2010 |
Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Male; Neurons; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
Combination of amlodipine and atorvastatin synergistically reduces leukocyte recruitment to mechanically injured mouse femoral artery.
Topics: Adoptive Transfer; Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Cell Adhesion; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Oxidative Stress; Pyrroles | 2011 |
Synergistic protection against vascular inflammation with a calcium channel blocker and a statin.
Topics: Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Mice; Pyrroles; Vasculitis | 2011 |
Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat.
Topics: Amlodipine; Animals; Atorvastatin; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nerve Degeneration; Neuroprotective Agents; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
Amlodipine and atorvastatin exert protective and additive effects via antiapoptotic and antiautophagic mechanisms after transient middle cerebral artery occlusion in Zucker metabolic syndrome rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Atorvastatin; Autophagy; Brain; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Pyrroles; Rats; Rats, Zucker | 2011 |
Three different spectrophotometric methods manipulating ratio spectra for determination of binary mixture of Amlodipine and Atorvastatin.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Heptanoic Acids; Pharmaceutical Preparations; Pyrroles; Sensitivity and Specificity; Spectrophotometry; Tablets | 2011 |
Trastuzumab-related palmar plantar erythrodysaesthesia.
Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agents; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Foot Dermatoses; Hand Dermatoses; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Trastuzumab | 2012 |
Combination therapy of atorvastatin and amlodipine inhibits sympathetic nervous system activation and improves cognitive function in hypertensive rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Antioxidants; Atorvastatin; Cognition; Drug Therapy, Combination; Heptanoic Acids; Hippocampus; Hypertension; Male; Nerve Tissue Proteins; Pyrroles; Rats; Rats, Inbred SHR; Superoxide Dismutase; Sympathetic Nervous System | 2012 |
Three different methods for determination of binary mixture of Amlodipine and Atorvastatin using dual wavelength spectrophotometry.
Topics: Absorption; Amlodipine; Atorvastatin; Heptanoic Acids; Methanol; Pyrroles; Reproducibility of Results; Spectrophotometry; Tablets | 2013 |
Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Chemokine CCL2; Cyclin-Dependent Kinase Inhibitor p21; Drug Therapy, Combination; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Sirtuin 1; Tumor Suppressor Protein p53 | 2013 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines; Carotid Stenosis; Diet, Mediterranean; Drug Therapy, Combination; Exercise Therapy; Ezetimibe; Female; Heptanoic Acids; Humans; Perindopril; Pyrroles; Risk; Stroke; Treatment Outcome; Ultrasonography; Vasodilator Agents | 2013 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its metabolites ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human plasma and its applicati
Topics: Amlodipine; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Liquid-Liquid Extraction; Male; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency | 2013 |
Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation.
Topics: Amlodipine; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apoptosis; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Matrix Metalloproteinases; Mice; Mice, Knockout; Pyrroles; rho-Associated Kinases | 2013 |
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fructose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Vasoconstriction; Vasodilation | 2014 |
Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy; Male; Nitric Oxide Synthase Type III; Pyrroles; Rats, Inbred Dahl; Scavenger Receptors, Class E; Sodium Chloride, Dietary; Superoxides; Time Factors; Vasodilation | 2014 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug Therapy, Combination; Female; Glucose; Heptanoic Acids; Humans; Hypertension; Inflammation; Kidney; Kidney Function Tests; Lipid Metabolism; Male; Multivariate Analysis; Oxidative Stress; Pyrroles; Regression Analysis; Renal Insufficiency, Chronic | 2014 |
Hollow-fiber-supported liquid membrane microextraction of amlodipine and atorvastatin.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Liquid Phase Microextraction; Pyrroles; Solid Phase Microextraction; Water Pollutants, Chemical | 2014 |
A calcified left ventricular mass.
Topics: Aged, 80 and over; Aging; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Calcinosis; Diagnosis, Differential; Female; Heart Neoplasms; Heart Valve Diseases; Heptanoic Acids; Humans; Hypertension; Mitral Valve; Monitoring, Physiologic; Platelet Aggregation Inhibitors; Pyrroles; Quinapril; Radiography; Tetrahydroisoquinolines; Treatment Outcome | 2014 |
If I had resistant hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Pyrroles; Spironolactone; Tetrazoles; Treatment Failure; Treatment Outcome | 2014 |
Advanced stability indicating chemometric methods for quantitation of amlodipine and atorvastatin in their quinary mixture with acidic degradation products.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Drug Stability; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Neural Networks, Computer; Spectrophotometry; Tablets | 2016 |
Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Cross-Sectional Studies; Disease Models, Animal; Gene Expression Profiling; Hydroxyproline; Hypertension; Immunohistochemistry; Male; Myocardium; NF-kappa B; Osteoprotegerin; RANK Ligand; Rats, Inbred SHR; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Ventricular Function, Left | 2016 |
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Linear Models; Male; Medication Adherence; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2016 |
Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blotting, Western; Drug Combinations; Gene Expression; Hypertension; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Random Allocation; Rats, Inbred SHR; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Ventricular Remodeling | 2016 |
Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-α, IL-1β and NF-κB inflammatory cytokine networks in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Atorvastatin; C-Reactive Protein; Cardiomegaly; Diastole; Heart Ventricles; I-kappa B Proteins; Inflammation; Interleukin-1beta; Male; Myocardium; NF-kappa B; Rats, Inbred SHR; Rats, Inbred WKY; Tumor Necrosis Factor-alpha | 2016 |
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Case-Control Studies; Disease Management; Drug Administration Schedule; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles | 2016 |
Development and Validation of highly Sensitive Stability Indicating Spectrofluorimetric Method for Determination of Amlodipine in Pharmaceutical Preparations and Human Plasma.
Topics: Amlodipine; Atorvastatin; Humans; Limit of Detection; Micelles; Pharmaceutical Preparations; Plasma; Spectrometry, Fluorescence; Tablets; Valsartan | 2016 |
Development and validation of HPLC and CE methods for simultaneous determination of amlodipine and atorvastatin in the presence of their acidic degradation products in tablets.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Calibration; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Combinations; Drug Stability; Electrophoresis, Capillary; Heptanoic Acids; Hydrochloric Acid; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Molecular Structure; Pyrroles; Reproducibility of Results; Tablets | 2016 |
Klippel-Trenaunay-Weber syndrome with atypical presentation of hypersplenism and nephrotic syndrome: a case report.
Topics: Adult; Allopurinol; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Arteriovenous Fistula; Atorvastatin; Cholecalciferol; Erythrocyte Transfusion; Humans; Hypersplenism; Klippel-Trenaunay-Weber Syndrome; Male; Nephrotic Syndrome; Perindopril; Port-Wine Stain; Vitamins | 2017 |
Does a fixed-dose combination of amlodipine and atorvastatin improve persistence with therapy in the Australian population?
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Australia; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Medication Adherence; Middle Aged; Patient Dropouts; Proportional Hazards Models; Risk Assessment | 2018 |
Quantification of amlodipine and atorvastatin in human plasma by UPLC-MS/MS method and its application to a bioequivalence study.
Topics: Adolescent; Adult; Amlodipine; Atorvastatin; Chromatography, High Pressure Liquid; Humans; Linear Models; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2018 |
Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study.
Topics: Amlodipine; Atorvastatin; Blood Pressure; Coronary Artery Disease; Drug Combinations; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Perindopril; Risk Factors | 2018 |
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Gout; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Purinergic P2Y Receptor Antagonists; Risk Factors; Uric Acid | 2018 |
Determination of amlodipine and atorvastatin mixture by different spectrophotometric methods with or without regression equations.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calibration; Drug Combinations; Limit of Detection; Powders; Regression Analysis; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2019 |
Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Comorbidity; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Perindopril; Prospective Studies | 2019 |
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Topics: Amlodipine; Anti-HIV Agents; Atorvastatin; Chromatography, High Pressure Liquid; Drug Interactions; HIV Infections; Humans; Linear Models; Metoprolol; Pravastatin; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Tandem Mass Spectrometry | 2019 |
Simultaneous estimation of amlodipine and atorvastatin by micelle-augmented first derivative synchronous spectrofluorimetry and multivariate analysis.
Topics: Algorithms; Amlodipine; Atorvastatin; Linear Models; Micelles; Multivariate Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2020 |
Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Italy; Lipids; Male; Medication Adherence; Middle Aged; Perindopril; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Effect of aging on adsorption behavior of polystyrene microplastics for pharmaceuticals: Adsorption mechanism and role of aging intermediates.
Topics: Adsorption; Amlodipine; Atorvastatin; Hydrogen Peroxide; Iron; Microplastics; Polystyrenes; Ultraviolet Rays; Water Pollutants, Chemical | 2020 |
Gastroretentive bilayer film for sustained release of atorvastatin calcium and immediate release of amlodipine besylate: pharmaceutical, pharmacokinetic evaluation, and IVIVC.
Topics: Acrylates; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Delayed-Action Preparations; Drug Liberation; Lactose; Male; Methylcellulose; Polymethacrylic Acids; Rabbits | 2020 |
Importance of fixed-dose combinations in cardiovascular prevention: the possibility of treating two diagnoses with a single pill.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hypertension; Perindopril | 2020 |
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Darunavir; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rosuvastatin Calcium; Treatment Outcome | 2020 |
Desorption of pharmaceuticals from pristine and aged polystyrene microplastics under simulated gastrointestinal conditions.
Topics: Adsorption; Amlodipine; Aquatic Organisms; Atorvastatin; Gastric Juice; Hydrogen-Ion Concentration; Intestinal Secretions; Microplastics; Oxidation-Reduction; Polystyrenes; Risk Assessment; Salinity; Temperature; Water Pollutants, Chemical | 2020 |
Effects of Switching from Treatment with Amlodipine and Atorvastatin Using Two Pills to an Equal Dose of Single-Pill Therapy in Japanese Outpatients.
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Retrospective Studies | 2020 |
The particulars of certain drugs' effect on the endogenous coenzyme Q10 plasma level in patients with cardiovascular diseases.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Tandem Mass Spectrometry; Ubiquinone | 2020 |
Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Humans; Hypertension; Mortality; Taiwan; Treatment Outcome | 2020 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management].
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Heart Disease Risk Factors; Humans; Hypertension; Perindopril; Risk Factors | 2021 |
Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin.
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biological Availability; Drug Combinations; Drug Interactions; Gastrointestinal Motility; Healthy Volunteers; Humans; Intestinal Absorption; Male; Ramipril; Young Adult | 2021 |
Combination of atorvastatin or hydrochlorothiazide/amlodipine with
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Drugs, Chinese Herbal; Humans; Hydrochlorothiazide; Hyperlipidemias; Hypertension; Pueraria; Salvia miltiorrhiza | 2021 |
Long-Term Incidence of Stroke and Dementia in ASCOT.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Dementia; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Risk Factors; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2021 |
Dose-dependent atorvastatin associated with angioedema.
Topics: Aged; Amlodipine; Angioedema; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Female; Humans; Hypertension; Losartan | 2022 |
The power of High Impact Amplitude Manipulation (HIAM) technique for extracting the basic spectra of two Fixed-dose combinations (FDC) -Spectrophotometric purity analysis via spectral contrast angle.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Drug Combinations; Spectrophotometry | 2022 |
Simultaneous Estimation of Telmisartan, Chlorthalidone, Amlodipine Besylate and Atorvastatin by RP-HPLC Method for Synchronous Assay of Multiple FDC Products Using Analytical FMCEA-Based AQbD Approach.
Topics: Amlodipine; Atorvastatin; Chlorthalidone; Chromatography, High Pressure Liquid; Telmisartan | 2023 |
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Perindopril | 2022 |
Atorvastatin and Fluvastatin Potentiate Blood Pressure Lowering Effect of Amlodipine through Vasorelaxant Phenomenon.
Topics: Amlodipine; Animals; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Calcium Channels; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Potassium Chloride; Rabbits; Rats; Rats, Wistar; Vasodilator Agents; Verapamil | 2023 |